ReviewNature reviews. Cancer2016
Epstein-Barr virus: more than 50 years old and still providing surprises.
Review in Nature reviews. Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05714748 (A Phase I Study of mRNA Vaccine for Patients With EBV-positive Advanced Malignant Tumors), which is not on this map. Cited by 552 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Study of mRNA Vaccine for Patients With EBV-positive Advanced Malignant Tumors
Who cites it
552 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Epstein-Barr Virus and Helicobacter pylori Co-Infection in Gastric Cancer: A Systematic Review and Meta-Analysis of Case-Control and Cross-Sectional Studies.Asian Pacific journal of cancer prevention : APJCP · 2026Pooled it
- Equity in protection: bridging global data gaps for an EBV vaccine-a systematic review and meta-analysis.BMJ global health · 2025Pooled it
- Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study.Blood advances · 2023Trial
- Functional contribution of Epstein-Barr virus BARF1 residues 35-39 to viable cell maintenance under serum deprivation and tumor formation.Virus genes · 2026Article
- Beyond oncogenesis: the unexplored benefits of viruses in cancer immunity.Nature reviews. Cancer · 2026Review
- CRISPR-Engineered CAR-T Cell Therapy for Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma: A Review of Emerging Therapeutic Prospects.Reviews in medical virology · 2026Review
- Article
- Infection-driven cancers in Asia: implications from epidemiological transitions.The Lancet regional health. Western Pacific · 2026Review
- Periconoid A, a Novel Ergosterol Derivative fromMarine drugs · 2026Article
- Sequence-Anchored Shared Tumor-Specific Epitopes for Pre-Manufactured HLA-Matched mRNA Cancer Vaccine Libraries: A Pan-Cancer Framework.Biomolecules · 2026Article
- Impact of deubiquitination of Epstein-Barr virus Rta and Zta on lytic development.Microbiology spectrum · 2026Article
- Role of soluble human leukocyte antigen-G in virus-associated cancers: A focused minireview.World journal of virology · 2026Review
- Immunosenescence and cancer predisposition in pediatric transplant recipients: An emerging paradigm.World journal of transplantation · 2026Review
- EBNA1 inhibitors reveal CDC7 and POU2F1 as direct functional targets in EBV epithelial cancers.mBio · 2026Article
- M.globosa promotes lung cancer progression and M2 macrophage polarization through oxidative phosphorylation.NPJ precision oncology · 2026Article
- A potent human neutralizing antibody targeting the receptor-binding site in the glycoprotein gp350 of Epstein-Barr virus.Science China. Life sciences · 2026Article
- Epstein-Barr Virus in Brain Cancer-Friend or Foe?International journal of molecular sciences · 2026Article
- Serum amyloid A kinetics predicts outcomes to PD-1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma.BMC cancer · 2026Article
- Intratumoral microbiota in cancer: molecular mechanism and therapeutic strategies.Molecular biomedicine · 2026Review
- Beyond the Usual Suspects: Emerging Associations Between Epstein-Barr Virus Infection/Infectious Mononucleosis and Cancers.Reviews in medical virology · 2026Review
492 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is more than 50 years since the Epstein-Barr virus (EBV), the first human tumour virus, was discovered. EBV has subsequently been found to be associated with a diverse range of tumours of both lymphoid and epithelial origin. Progress in the molecular analysis of EBV has revealed fundamental mechanisms of more general relevance to the oncogenic process. This Timeline article highlights key milestones in the 50-year history of EBV and discusses how this virus provides a paradigm for exploiting insights at the molecular level in the diagnosis, treatment and prevention of cancer.
Indexed as
Identifiers
27687982What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.